Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities: 2013-2025

Historic Cash from Financing Activities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to -$4.3 million.

  • Amphastar Pharmaceuticals' Cash from Financing Activities rose 80.95% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.9 million, marking a year-over-year increase of 12.00%. This contributed to the annual value of -$81.0 million for FY2024, which is 117.83% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Cash from Financing Activities is -$4.3 million, which was up 85.61% from -$30.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash from Financing Activities ranged from a high of $428.1 million in Q2 2023 and a low of -$47.1 million during Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$13.6 million (2024), whereas its average is $29.5 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Cash from Financing Activities plummeted by 3,730.84% in 2021 and then spiked by 43,169.52% in 2023.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Cash from Financing Activities stood at -$8.7 million in 2021, then crashed by 85.86% to -$16.2 million in 2022, then plummeted by 191.32% to -$47.1 million in 2023, then grew by 28.12% to -$33.8 million in 2024, then soared by 80.95% to -$4.3 million in 2025.
  • Its Cash from Financing Activities stands at -$4.3 million for Q3 2025, versus -$30.2 million for Q2 2025 and -$14.5 million for Q1 2025.